A Randomized, Double-Blinded, Placebo-Controlled Trial Evaluating the Virological Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Sirolimus Adjuvant Therapy in Patients With Coronavirus Disease (COVID-19)
Latest Information Update: 06 Dec 2021
At a glance
- Drugs Sirolimus (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- Acronyms SirCO-1
Most Recent Events
- 02 Dec 2021 Planned End Date changed from 1 Aug 2021 to 30 Jul 2021.
- 02 Dec 2021 Planned primary completion date changed from 1 Jul 2021 to 30 Jul 2021.
- 03 Dec 2020 Status changed from suspended to discontinued as study population not regularly admitted to hospital and approaches have shifted away from repurposing old drugs.